New Release: Alpha testing version has been released.

Cefadroxil

J01D - Other beta-lactam antibacterials ATC J01DA09 Small molecule approved 1978 Oral Natural product

🧬 Cross-allergy: Cephalosporins

JFDA label: Biodroxil 125mg suspension

Mechanism of Action

Inhibitor of Bacterial penicillin-binding protein — Bacterial penicillin-binding protein inhibitor

TargetActionGene / class
Bacterial penicillin-binding protein efficacy INHIBITOR

Indications

Approved

  • Pharyngitis and/or tonsillitis
  • Skin and skin structure infections
  • Urinary tract infection

Off-label

  • Prosthetic joint infection with Staphylococci (oxacillin-susceptible)

Antimicrobial Spectrum

Expected / intrinsic spectrum (EUCAST breakpoints & labels) — not local resistance. Source: EUCAST v16 · openfda-label.

Bacteria

OrganismActivityMIC
Acinetobacter calcoaceticus Active
Enterobacterales Susceptible 16.0 mg/L
Enterococcus faecalis Active
Enterococcus faecium Active
Escherichia coli Active
Morganella morganii Active
Proteus mirabilis Active
Proteus morganii Active
Staphylococcus aureus Active
Streptococcus faecalis Active
Streptococcus faecium Active
Streptococcus pyogenes Active

Class profile

gramStatusBoth
spectrumBreadthModerate
atypicalCoverageNo
isBactericidal1
moaCategoryCell wall synthesis inhibitor (beta-lactam, 1st generation cephalosporin)
pdIndexTime-dependent
postAntibioticEffectNone
mrsaCoverage0
resistanceMechanismsBeta-lactamase production,PBP mutations

Contraindications

Source: Lexicomp

  • Hypersensitivity to cefadroxil, any component of the formulation, or other cephalosporins Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Other (1)

Common Gastrointestinal: Diarrhea

Dosing

Source: Lexicomp

Cystitis, acute uncomplicated (alternative agent): Oral: 500 mg twice daily for 5 to 7 days (Greenberg 1986; Hooton 2018) Pharyngitis: Oral: Manufacturer’s labeling: 1 g/day in a single or 2 divided doses for 10 days Alternate dosing: 30 mg/kg/dose once daily (maximum: 1 g daily) for 10 days (Shulman 2012). Note: Recommended as an alternative agent in penicillin-allergic patients; however, avoid in patients with immediate type hypersensitivity to penicillin. Prosthetic joint infection, staphylococci (oxacillin-susceptible), chronic oral antimicrobial suppression (off-label use): 500 mg every 12 hours (Osmon 2013) Skin and skin structure infections: Oral: 1 g daily in a single or 2 divided doses Tonsillitis: Oral: 1 g daily in a single or 2 divided doses for 10 days
(For additional information see "Cefadroxil: Pediatric drug information") Pharyngitis: Children and Adolescents: Oral: Manufacturer’s labeling: 30 mg/kg/day in a single dose or divided every 12 hours Alternate dosing: Refer to adult dosing Skin and skin structure infections: Children and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours. For impetigo: 30 mg/kg/day in a single dose or divided every 12 hours. Tonsillitis: Children and Adolescents: Oral: 30 mg/kg/day in a single dose or divided every 12 hours Urinary tract infections: Children and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours
Refer to adult dosing.
Initial: 1 g as a single dose. Maintenance: CrCl >50 mL/minute: No dosage adjustment necessary. CrCl 25 to 50 mL/minute: 500 mg every 12 hours. CrCl 10 to 25 mL/minute: 500 mg every 24 hours. CrCl
There are no dosage adjustments provided in the manufacturer’s labeling.

Warnings & Precautions

Source: Lexicomp

Hypersensitivity reactions

Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.

Penicillin allergy

Use with caution in patients with a history of penicillin allergy.

Superinfection

Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Disease-related concerns:

Colitis

Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

Renal impairment

Use with caution in patients with renal impairment (CrCl 2); dosage adjustment may be needed. Concurrent drug therapy issues:

Drug-drug interactions

Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Dosage form specific issues:

Benzyl alcohol and derivatives

Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

Propylene glycol

Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer’s labeling

Suspension

May contain sulfur dioxide (sulfite); hypersensitivity reactions, including anaphylaxis and/or asthmatic exacerbations, may occur (may be life threatening). Other warnings/precautions:

Appropriate use

Only IM penicillin has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx; efficacy data for cefadroxil in the prophylaxis of subsequent rheumatic fever episodes are not available.

Pregnancy & Lactation

Pregnancy

FDA category B

Adverse events have not been observed in animal reproduction studies. Cefadroxil crosses the placenta. Limited data is available concerning the use of cefadroxil in pregnancy; however, adverse fetal effects were not noted in a small clinical trial.

Lactation

Very small amounts of cefadroxil are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefadroxil to nursing women. Nondose-related effects could include modification of bowel flora.

Monitoring

EfficacyCulture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin)
ToxicityRenal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea)
Clinical pearlCulture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship).
CounselingComplete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h.

Chemistry & Properties

2D structure
FormulaC16H17N3O5S
Molecular weight363.39 g/mol
IUPAC name(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS50370-12-2
PubChem CID47965
InChIKeyBOEGTKLJZSQCCD-UEKVPHQBSA-N
logP0.15 (XLogP -2.1)
Polar surface area132.96 Ų
H-bond acceptors / donors6 / 4
Drug-likeness (QED)0.56
Lipinski violations0
SMILESCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantNo

Enzyme interactions

EnzymeRoleDetail
CYP2D6Substrate

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MCT1 (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OAT1 (Inhibitor)OAT2 (Inhibitor)OAT3 (Inhibitor)OAT4 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OATP2B1 (Inhibitor)OCTN2 (Inhibitor)P-gp (Inhibitor)PEPT1 (Inhibitor)PEPT2 (Inhibitor)BCRP (Substrate)MRP1 (Substrate)MRP2 (Substrate)MRP3 (Substrate)MRP4 (Substrate)OATP1B3 (Substrate)P-gp (Substrate)PEPT1 (Substrate)PEPT2 (Substrate)

Drug–drug interactions (8, DDInter)

Interacting drugSeverityManagement
Balsalazide moderate
Chloramphenicol moderate
Dicoumarol moderate
Ethinylestradiol moderate
Mycophenolic acid moderate
Pemetrexed moderate
Picosulfuric acid moderate
Warfarin moderate

Registered Products (23)

BrandForm / strengthPackAgentCitizen (JOD)
Biodroxil Suspension 125 mg/5 ml 60 ml pack varies Nabulsi Drug Store 1.570
Droxil Suspension 250 mg/5 ml 60 ml UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN 1.920
Midroxil Dry Suspension Suspension 250 mg/5 ml 60 ml pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 2.060
Biodroxil Suspension 125 mg/5 ml 100 ml pack varies Nabulsi Drug Store 2.610
Cefadril-250 suspension. Suspension 250 mg/5 ml 60 ml AL-RAM PHARMA.INDUS.CO.LTD/JORDAN 2.750
Droxicef sus Suspension 250 mg/5 ml 60 ml Pharma International Company/ Jordan 2.750
Midroxil Capsules Capsule 500 mg 12 cap pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 2.880
Midroxil Dry Suspension Suspension 250 mg/5 ml 100 ml pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 3.430
Cedrox 500 Capsules Capsule 500 mg 12 cap Hikma Pharmaceuticals Co.Ltd/Jordan 4.600
Cefadril-500mg cap. Capsule 500 mg 12 cap pack varies AL-RAM PHARMA.INDUS.CO.LTD/JORDAN 4.600
Droxicef cap Capsule 500 mg 12 cap Pharma International Company/ Jordan 4.600
Droxil Capsules Capsule 500 mg 12 cap pack varies UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN 4.600
Midroxil Capsules Capsule 500 mg 20 cap pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 4.800
Cedrox 500 Suspension Suspension 500 mg/5 ml 60 ml Hikma Pharmaceuticals Co.Ltd/Jordan 5.210
Midroxil Dry Suspension Suspension 500 mg/5 ml 60 ml pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 5.210
Droxicef tab Tablet 1 g 10 tab Pharma International Company/ Jordan 6.150
Cedrox Tablet 1 g 12 tab Hikma Pharmaceuticals Co.Ltd/Jordan 8.070
Midroxil Dry Suspension Suspension 500 mg/5 ml 100 ml pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 8.680
Droxil Capsules Capsule 500 mg 300 cap pack varies UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN 94.300
Midroxil Capsules Capsule 500 mg 500's pack varies MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN 102.000
Cefadril-500mg cap. Capsule 500 mg 600 cap pack varies AL-RAM PHARMA.INDUS.CO.LTD/JORDAN 174.800
Cefadril-500mg cap. Capsule 500 mg 700 cap pack varies AL-RAM PHARMA.INDUS.CO.LTD/JORDAN 183.670
Cefadril-500mg cap. Capsule 500 mg 1200 cap pack varies AL-RAM PHARMA.INDUS.CO.LTD/JORDAN 349.600